Velcade gains new indication
Millenium Pharmaceutical's oncologic Velcade (bortezomib) is approved for mantle cell lymphoma (MCL) in patients who have received at least one prior therapy, the company announces Dec. 8. MCL is a relatively uncommon and aggressive subtype of non-Hodgkins lymphoma for which there is no cure in the relapsed or refractory setting. The condition has a U.S. prevalence of 10,000 patients. The approval was based on the company's Phase II PINNACLE trial, a single-arm, open-label study that enrolled 155 patients and showed an overall response rate of 31%. Velcade is currently the market leader in multiple myeloma for patients who have received one prior therapy. The drug is being codeveloped with Johnson & Johnson...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.